ProCE Banner Activity

Expert Guidance on Treatment Advances in Acute Myeloid Leukemia

Slideset Download
Download these expert-selected slides on acute myeloid leukemia to help provide optimal treatment for your patients with AML.

Released: October 21, 2021

Expiration: October 20, 2022

Share

Faculty

Amir Fathi

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Bristol Myers Squibb

Genentech, a member of the Roche Group

Jazz Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Amir T. Fathi, MD, has disclosed that he has received consulting fees from AbbVie, Agios/Servier, Amgen, Blueprint, Bristol Myers Squibb, Daiichi Sankyo, Foghorn, Forma, Forty Seven, Genentech, Ipsen, Kite, Kura Oncology, Morphosys, New Link Genetics, Novartis, Pfizer, Seattle Genetics, Takeda, Trillium, and Trovagene and funds for research support from AbbVie, Agios/Servier, and Celgene/Bristol Myers Squibb.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, Bristol Myers Squibb, Celgene, Genentech, Gilead Sciences, GlaxoSmithKline, Jazz, Kite, Kura Oncology, Mana, Novartis, Pfizer, Rafael, Stemline, and Takeda and fees for non-CME/CE services from Astellas, Dava Oncology, Jazz, Kura Oncology, Pfizer, and Stemline.